Denosumab for prevention of fractures in postmenopausal women with osteoporosis.
暂无分享,去创建一个
Claus Christiansen | Cesar Libanati | Michael R McClung | Richard Eastell | Pierre Delmas | Andrea Wang | S. Cummings | C. Christiansen | I. Reid | R. Eastell | P. Delmas | J. S. San Martin | E. Siris | J. Zanchetta | S. Adami | M. McClung | Andrea T Wang | C. Libanati | M. Austin | Steven R Cummings | Š. Kutílek | H. Zoog | S. Siddhanti | Silvano Adami | Matt Austin | Ian R Reid | Ethel S Siris | Jose Zanchetta | Javier San Martin | Holly B Zoog | Stepan Kutilek | Suresh Siddhanti
[1] M. Whyte. The long and the short of bone therapy. , 2006, The New England journal of medicine.
[2] T. Martin,et al. Paracrine regulation of osteoclast formation and activity: milestones in discovery. , 2004, Journal of musculoskeletal & neuronal interactions.
[3] P. Miller,et al. Two‐Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[4] N. Watts,et al. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy , 2008, Osteoporosis International.
[5] Martin Tj. Paracrine regulation of osteoclast formation and activity: milestones in discovery. , 2004 .
[6] O. Johnell,et al. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures , 2006, Osteoporosis International.
[7] S. Cummings,et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.
[8] M. Bouxsein,et al. Considerations for Development of Surrogate Endpoints for Antifracture Efficacy of New Treatments in Osteoporosis: A Perspective , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[9] S. Cummings,et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. , 2007, The New England journal of medicine.
[10] P. Delmas. Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases. , 2008, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.
[11] David L. Lacey,et al. Osteoclast differentiation and activation , 2003, Nature.
[12] S. Cummings,et al. Recommendations for the Clinical Evaluation of Agents for Treatment of Osteoporosis: Consensus of an Expert Panel Representing the American Society for Bone and Mineral Research (ASBMR), the International Society for Clinical Densitometry (ISCD), and the National Osteoporosis Foundation (NOF) , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[13] C. Christiansen,et al. Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[14] R. Kagan,et al. Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis , 2004, Current medical research and opinion.
[15] J. S. San Martin,et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. , 2008, Bone.
[16] Jacques P. Brown,et al. Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[17] P. Miller,et al. Denosumab in Postmenopausal Women with Low Bone Mineral Density , 2007 .
[18] M. Nevitt,et al. Vertebral fracture assessment using a semiquantitative technique , 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[19] Gail A. Greendale,et al. Outcomes of Osteoporotic Fractures , 2001 .
[20] S. Boonen,et al. Risedronate Rapidly Reduces the Risk for Nonvertebral Fractures in Women with Postmenopausal Osteoporosis , 2004, Calcified Tissue International.
[21] R. Goodman,et al. The effect of risedronate on the risk of hip fracture in elderly women. , 2001, The New England journal of medicine.
[22] H. Genant,et al. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. , 1993, The American journal of medicine.
[23] R. Vines. THE LONG AND THE SHORT , 1977, The Medical journal of Australia.
[24] J. Kalbfleisch,et al. The Statistical Analysis of Failure Time Data , 1980 .
[25] J. Reginster,et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. , 2001, The New England journal of medicine.
[26] A. LaCroix,et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. , 1998, JAMA.
[27] V. French,et al. The long and the short of it , 1993, Nature.
[28] S. Cummings,et al. BMD at Multiple Sites and Risk of Fracture of Multiple Types: Long‐Term Results From the Study of Osteoporotic Fractures , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[29] P. Tugwell,et al. Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. , 2024, The Cochrane database of systematic reviews.
[30] A. Capron,et al. Osteoporosis Panel Summary , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[31] Chantal Couture,et al. Mechanisms of action , 1994, Schizophrenia Research.
[32] J. S. San Martin,et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. , 2008, The Journal of clinical endocrinology and metabolism.
[33] S. Silverman,et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. , 2006, Mayo Clinic proceedings.
[34] J. Adachi,et al. Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. , 2002, Archives of internal medicine.
[35] G. Guyatt,et al. Ethical Issues in Stopping Randomized Trials Early Because of Apparent Benefit , 2007, Annals of Internal Medicine.
[36] M. Hooper,et al. Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis , 2000, Osteoporosis International.
[37] Alan Agresti,et al. Categorical Data Analysis , 2003 .
[38] H K Genant,et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. , 1999, JAMA.
[39] P. Tugwell,et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. , 2008, The Cochrane database of systematic reviews.
[40] S. Cummings,et al. Epidemiology and outcomes of osteoporotic fractures , 2002, The Lancet.
[41] S. Silverman,et al. Bisphosphonate‐Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.